Dr. Farago is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
Boston, MA 02114Phone+1 617-724-4000
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2010 - 2014- Brigham and Women's HospitalResidency, Internal Medicine, 2008 - 2010
Harvard Medical SchoolClass of 2008
Certifications & Licensure
MA State Medical License 2010 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy Start of enrollment: 2015 Oct 13
- Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer Start of enrollment: 2016 Jan 25
Publications & Presentations
PubMed
- 254 citationsEGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical OutcomesNicolas Marcoux, Scott N. Gettinger, Grainne M. O'Kane, Kathryn C. Arbour, Joel W. Neal
Journal of Clinical Oncology. 2019-02-01 - 324 citationsRegulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell ResponsesNikhil S. Joshi, Elliot H. Akama-Garren, Yisi Lu, Da-Yae Lee, Gregory P. Chang
Immunity. 2015-09-15 - 146 citationsClinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion.Anna F. Farago, Martin S. Taylor, Robert C. Doebele, Viola W. Zhu, Shivaani Kummar
JCO Precision Oncology. 2017-05-30
Lectures
- Safety and efficacy of combination olaparib (O) and temozolomide (T) in small cell lung cancer (SCLC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
- ATLANTIS: Global, randomized phase III study of lurbinectedin (L) with doxorubicin (DOX) vs. CAV or topotecan (T) in small-cell lung cancer after platinum therapy.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Press Mentions
Combining Forces in Small Cell Lung CancerNovember 21st, 2019
Potential New Treatment Strategy for Relapsed SCLCSeptember 11th, 2019
PARP Inhibitor Combination Shows Activity in Small Cell Lung CancerAugust 21st, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
